OSE 2101
Alternative Names: EP-2101; IDM 2101; OSE-2101; TedopiLatest Information Update: 12 Sep 2024
At a glance
- Originator IDM Pharma
- Developer Bristol-Myers Squibb; GERCOR; OSE Immunotherapeutics
- Class Antineoplastics; Cancer vaccines; Immunotherapies
- Mechanism of Action T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase III Non-small cell lung cancer
- Phase II Breast cancer; Colorectal cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer
Most Recent Events
- 10 Sep 2024 Phase-III clinical trials in Non-small cell lung cancer (Metastatic disease, Second-line therapy or greater, Monotherapy) in USA, Europe, United Kingdom, Canada(SC) (NCT06472245)
- 03 Apr 2024 US FDA approved two dossiers for OSE 2101 in Non-small cell lung cancer
- 27 Mar 2024 OSE Immunotherapeutics announces intention to submit a dossier to Europe in December 2024